FDA approves Rituxan as first targeted B-cell therapy for treatment of rheumatoid arthritis
02-Mar-2006 -
Genentech, Inc. and Biogen Idec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved, following Priority Review, the therapeutic antibody Rituxan® (Rituximab) in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with ...
autoimmune diseases
Biogen Idec
food
+11